Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Allogene Therapeutics Inc ALLO

Healthcare Biotechnology
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALLO)

Allogene Therapeutics Announces Q2 Investor Conference Participation

GlobeNewswire 8 days ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

GlobeNewswire March 14, 2024

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

GlobeNewswire March 12, 2024

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

GlobeNewswire March 5, 2024

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

GlobeNewswire February 28, 2024

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

GlobeNewswire February 16, 2024

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire January 16, 2024

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

GlobeNewswire January 4, 2024

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

GlobeNewswire January 4, 2024
View More News ››

Opinion & Analysis (NDAQ:ALLO)

Allogene Therapeutics Shares Climb 30% on Phase 1 Relapsed/Refractory NHL Study Data

Streetwise Reports May 15, 2020
View More Opinion ››

Bullboard Posts (NDAQ:ALLO)

Be the first to post on this bullboard.

Benton Resources Inc.

Benton Resources Inc.

Benton Resources Inc. is a mineral exploration company listed on the TSX Venture Exchange under the symbol BEX. Benton has a ...
View More »